Evidence map›Paper›PMID 36177048›Full record

ReviewFrontiers in immunology2022

Inborn errors of immunity and related microbiome.

Raja Hazime, Fatima-Ezzohra Eddehbi, Saad El Mojadili, Nadia Lakhouaja, Ikram Souli, Abdelmouïne Salami, Bouchra M'Raouni, Imane Brahim, Mohamed Oujidi, Morad Guennouni and 2 more

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Observational
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Raja HazimeLaboratory of Immunology, Center of Clinical Research, Mohammed VI University Hospital, Marrakech, Morocco.
Fatima-Ezzohra EddehbiLaboratory of Immunology, Center of Clinical Research, Mohammed VI University Hospital, Marrakech, Morocco.
Saad El MojadiliLaboratory of Immunology, Center of Clinical Research, Mohammed VI University Hospital, Marrakech, Morocco.
Nadia LakhouajaLaboratory of Immunology, Center of Clinical Research, Mohammed VI University Hospital, Marrakech, Morocco.
Ikram SouliLaboratory of Immunology, Center of Clinical Research, Mohammed VI University Hospital, Marrakech, Morocco.
Abdelmouïne SalamiLaboratory of Immunology, Center of Clinical Research, Mohammed VI University Hospital, Marrakech, Morocco.
Bouchra M'RaouniLaboratory of Immunology, Center of Clinical Research, Mohammed VI University Hospital, Marrakech, Morocco.
Imane BrahimLaboratory of Immunology, Center of Clinical Research, Mohammed VI University Hospital, Marrakech, Morocco.
Mohamed OujidiLaboratory of Immunology, Center of Clinical Research, Mohammed VI University Hospital, Marrakech, Morocco.
Morad GuennouniLaboratory of Immunology, Center of Clinical Research, Mohammed VI University Hospital, Marrakech, Morocco.
Ahmed Aziz BousfihaPediatric infectious and Immunology Department, Ibn Rochd University Hospital, Casablanca, Morocco.
Brahim AdmouLaboratory of Immunology, Center of Clinical Research, Mohammed VI University Hospital, Marrakech, Morocco.
Centre Hospitalier Universitaire Mohammed VI · MACadi Ayyad University · MACentre Hospitalier Universitaire Ibn Rochd · MA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inborn errors of immunity (IEI) are characterized by diverse clinical manifestations that are dominated by atypical, recurrent, chronic, or severe infectious or non-infectious features, including autoimmunity, lymphoproliferative disease, granulomas, and/or malignancy, which contribute substantially to morbidity and mortality. Some data suggest a correlation between clinical manifestations of IEI and altered gut microbiota. Many IEI display microbial dysbiosis resulting from the proliferation of pro-inflammatory bacteria or a decrease in anti-inflammatory bacteria with variations in the composition and function of numerous microbiota. Dysbiosis is considered more established, mainly within common variable immunodeficiency, selective immunoglobulin A deficiency, severe combined immunodeficiency diseases, Wiskott-Aldrich syndrome, Hyper-IgE syndrome, autoimmune polyendocrinopathy-candidiasis-ectodermal-dystrophy (APECED), immune dysregulation, polyendocrinopathy, enteropathy X-linked (IPEX) syndrome, IL-10 receptor deficiency, chronic granulomatous disease, and Kostmann disease. For certain IEIs, the specific predominance of gastrointestinal, respiratory, and cutaneous involvement, which is frequently associated with dysbiosis, justifies the interest for microbiome identification. With the better understanding of the relationship between gut microbiota, host immunity, and infectious diseases, the integration of microbiota modulation as a therapeutic approach or a preventive measure of infection becomes increasingly relevant. Thus, a promising strategy is to develop optimized prebiotics, probiotics, postbiotics, and fecal microbial transplantation to rebalance the intestinal microbiota and thereby attenuate the disease activity of many IEIs.

Indexed as

Gastrointestinal MicrobiomeImmune System DiseasesDysbiosisHumansImmunoglobulin AReceptors, Interleukin-10Immunoglobulin AReceptors, Interleukin-10diagnostic strategydysbiosisinborn errors of immunitymicrobiometherapeutic strategies

Identifiers

PMID36177048
PMCPMC9513548
OpenAlexW4295412909

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.